ClinicalTrials.gg
CompletedNCT06653296Updated Sep 17, 2025

A Dose-Response Safety Study of ENX-102 in Patients With GAD

A Phase 2 interventional study of ENX-102 and Placebo in General Anxiety Disorder, sponsored by Engrail Therapeutics INC. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Engrail Therapeutics INC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Generalized Anxiety Disorder with a site in United Kingdom — 5 open to participants now, 6 under way, 1 of them phase 3. Generalized Anxiety Disorder · United Kingdom.

Enrollment
10th of 12
38 · median 100
Started
2024
with 1 other
Phase 2
2 of 15
1 open now
Registered
10th of 15
by date
Lead sponsor
1 of 15
Engrail Therapeutics INC

Among the 15 studies in Generalized Anxiety Disorder with a site in United Kingdom, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 2, and was the 10th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

5 of the 15 studies in Generalized Anxiety Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Generalized Anxiety Disorder with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD

03

Conditions studied

  • General Anxiety Disorder

Keywords

  • anxiety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female, inclusive of any gender identity, aged 18 to 65 years, inclusive
  • Diagnosed with GAD according to the , confirmed by MINI
  • Experiencing generalized anxiety as measured by HAM-A score ≥18 and at least moderately severe core symptoms of anxious mood and tension as measured by HAM-A Items 1 and 2, respectively, with scores each ≥2

Key Exclusion Criteria:

  • Clinically predominant psychiatric diagnosis other than GAD per the MINI
  • Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or current posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder
  • Ingested prohibited medication within 5 half-lives prior to Day 1
  • Current or recent moderate or severe substance use disorder as assessed by the MINI
  • Unwilling or unable to abstain from alcohol or other recreational psychoactive substances such as marijuana during participation in the trial
  • Has significant progressive disorders or unstable medical conditions
  • Is unable to comply with the requirements of the study or, in the opinion of the Investigator, is unsuitable for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    ENX-102 low-dose

    ENX-102

    Drug: ENX-102

  • Experimental
    ENX-102 mid-dose

    ENX-102

    Drug: ENX-102

  • Experimental
    ENX-102 high-dose

    ENX-102

    Drug: ENX-102

Interventions

  • Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period

    Also known as: ENX-102 low-dose, ENX-102 mid-dose, ENX-102 high-dose

  • DrugPlacebo

    Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    • Incidence and severity of treatment-emergent AEs (TEAEs)

    Time frame: 4 weeks

07

Study locations

3 sites
  • MAC Clinical Research
    Liverpool, UK, United Kingdom
  • MAC Clinical Research
    Blackpool, United Kingdom
  • MAC Clinical Research
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jun 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2024
First posted
Oct 22, 2024
StartActual
Dec 9, 2024
Primary completionActual
Jun 23, 2025
CompletionActual
Jun 23, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06653296
Lead sponsor
Engrail Therapeutics INC
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Dec 9, 2024
Primary completion
Jun 23, 2025
Completion
Jun 23, 2025
Last update
Sep 17, 2025

Study contacts

Kimberly Vanover, PhD
study director · Engrail Therapeutics INC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENX-102

Start the discussion